Kottom T, Carmona E, Schaefbauer K, Stelzig K, Pellegrino M, Bindzus M
Infect Immun. 2025; 93(2):e0027624.
PMID: 39745390
PMC: 11834440.
DOI: 10.1128/iai.00276-24.
Wills N, Tavares J, Said-Hartley Q, Wasserman S
South Afr J HIV Med. 2024; 25(1):1636.
PMID: 39649953
PMC: 11622136.
DOI: 10.4102/sajhivmed.v25i1.1636.
Mappin-Kasirer B, Del Corpo O, Gingras M, Hass A, Hsu J, Costiniuk C
BMC Infect Dis. 2024; 24(1):1032.
PMID: 39333914
PMC: 11429489.
DOI: 10.1186/s12879-024-09957-y.
Jackson I, Isern R, Jesina S, Velagapudi M, Pruett W
Ochsner J. 2024; 24(3):225-228.
PMID: 39280872
PMC: 11398631.
DOI: 10.31486/toj.24.0024.
Khan S, Ahmad B
Ochsner J. 2024; 24(3):167.
PMID: 39280865
PMC: 11398629.
DOI: 10.31486/toj.24.0088.
Preclinical and Toxicology Assessment of ALW-II-41-27, an Inhibitor of the Eph Receptor A2 (EphA2).
Kottom T, Stelzig K, Pellegrino M, Bindzus M, Yi E, Limper A
Drugs R D. 2024; 24(3):425-434.
PMID: 39105996
PMC: 11455733.
DOI: 10.1007/s40268-024-00483-5.
Excavation of Biomarker Candidates for the Diagnosis of Infection via Genome-Wide Prediction and Functional Annotation of Secreted Proteins.
Dan J, Wei W, Ou W, Gao G, Song W, Ye L
ACS Omega. 2024; 9(25):27093-27103.
PMID: 38947822
PMC: 11209904.
DOI: 10.1021/acsomega.4c00571.
Clinical Characteristics and Prognostic Predictors of Pneumocystis Pneumonia in Patients with and without Chronic Pulmonary Disease: A Retrospective Cohort Study.
Feng Q, Tong Z
Infect Drug Resist. 2024; 17:2169-2182.
PMID: 38832106
PMC: 11146626.
DOI: 10.2147/IDR.S456716.
Chest X-ray Features of HIV-Associated Pneumonia (PCP) in Adults: A Systematic Review and Meta-analysis.
Wills N, Adriaanse M, Erasmus S, Wasserman S
Open Forum Infect Dis. 2024; 11(4):ofae146.
PMID: 38628951
PMC: 11020241.
DOI: 10.1093/ofid/ofae146.
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T
Clin Microbiol Rev. 2024; 37(2):e0007423.
PMID: 38602408
PMC: 11237431.
DOI: 10.1128/cmr.00074-23.
Progress in the application of nanoparticles for the treatment of fungal infections: A review.
Zhu X, Chen Y, Yu D, Fang W, Liao W, Pan W
Mycology. 2024; 15(1):1-16.
PMID: 38558835
PMC: 10977003.
DOI: 10.1080/21501203.2023.2285764.
Thirteen Cases of Pulmonary Pneumocystis in HIV-Negative Patients.
Bouhamdi A, Es-Sabbahi B, Amiali R, Serraj M, Biaz M, Benjelloun M
Cureus. 2023; 15(8):e43409.
PMID: 37706120
PMC: 10496727.
DOI: 10.7759/cureus.43409.
pneumonia presenting as a large pulmonary mass in a patient with AIDS.
Bolling T, Beal S, Caulkins H, Wang G
BMJ Case Rep. 2023; 16(7).
PMID: 37524509
PMC: 10391796.
DOI: 10.1136/bcr-2022-253563.
Novel Antigens for Seroprevalence Studies.
Pungan D, Fan J, Dai G, Shamima Khatun M, Dietrich M, Zwezdaryk K
J Fungi (Basel). 2023; 9(6).
PMID: 37367538
PMC: 10300987.
DOI: 10.3390/jof9060602.
Quick versus Quantitative: Evaluation of Two Commercial Real-Time PCR Assays for the Detection of Pneumocystis jirovecii from Bronchoalveolar Lavage Fluids.
Belanger C, Locher K, Velapatino B, Dufresne P, Eckbo E, Charles M
Microbiol Spectr. 2023; 11(4):e0102123.
PMID: 37260378
PMC: 10434167.
DOI: 10.1128/spectrum.01021-23.
The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients.
Zhang Z, Li Q, Shen X, Liao L, Wang X, Song M
Front Pharmacol. 2022; 13:957376.
PMID: 36160421
PMC: 9490050.
DOI: 10.3389/fphar.2022.957376.
Targeted NGS-Based Analysis of Reveals Novel Genotypes.
Pungan D, Eddens T, Song K, Lakey M, Crovetto N, Arora S
J Fungi (Basel). 2022; 8(8).
PMID: 36012851
PMC: 9409852.
DOI: 10.3390/jof8080863.
Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids.
Sadek M, Loizidou A, Drowart A, van den Wijngaert S, Gomez-Galdon M, Aspeslagh S
J Immunother Precis Oncol. 2022; 3(1):27-30.
PMID: 35756180
PMC: 9208388.
DOI: 10.4103/JIPO.JIPO_23_19.
pneumonia in a patient receiving chemotherapy for advanced prostatic cancer: a case report.
Tiantian C, Jin Y, Jing Z, Jing F, Xiaoyan J
J Int Med Res. 2022; 50(6):3000605221105358.
PMID: 35751409
PMC: 9237926.
DOI: 10.1177/03000605221105358.
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9.
Kottom T, Schaefbauer K, Carmona E, Yi E, Limper A
Drugs R D. 2022; 22(2):165-173.
PMID: 35486318
PMC: 9167333.
DOI: 10.1007/s40268-022-00389-0.